Roth Capital reissued their buy rating on shares of CorMedix (NASDAQ:CRMD) in a report released on Thursday. Roth Capital currently has a $6.00 price target on the stock.

CRMD traded down $0.03 during trading on Thursday, hitting $1.62. The company’s stock had a trading volume of 6,964,858 shares.

CorMedix (NASDAQ:CRMD) last issued its quarterly earnings data on Wednesday, November 14th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $0.05 million.

About CorMedix

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Further Reading: Stock Symbols and CUSIP Explained

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.